The University of Wisconsin Madison has a long and rich history as an international leader in basic, translational and clinical cancer research. Its history reflects the development of two NCI designated cancer research centers founded by Dr. Harold Rusch on the campus of UW Madison. The McArdle Laboratory for Cancer Research was founded in 1940 and the University of Wisconsin Comprehensive Cancer Center was awarded NCI funding as one of the first comprehensive cancer centers in 1973. Today the University of Wisconsin Comprehensive Cancer Center is comprised of 253 members from 52 departments and 9 schools of the University of Wisconsin Madison. The organizational structure that brings together this diverse community of investigators is centered around seven scientific research programs and fifteen Disease Oriented Working Groups. Together the members receive $105M in direct cost funding for cancer related research, $89M is peer-reviewed. $28M is from NCI, $51M from other NIH Institutes, and $10M from other peer-reviewed sources. The three highest goals of the UWCCC, now and for the future, are: 1) to conduct the highest quality research into the origins and control of cancer; 2) to translate these research findings to evaluation in the clinic through well designed clinical trials with corresponding biologic endpoints whenever possible;and 3) to provide the best care possible to all cancer patients by carefully integrating high quality cutting edge care with clinical research in a compassionate and individualized manner. To address these goals during the next grant period, UWCCC priorities for future development will be: * Strengthening of programmatic cancer focused intra- and transdisciplinary basic and clinical research capabilities especially in Aging and Cancer and in Immunology * Focus research on health disparities and the delivery of outstanding cancer care to all populations * Enhancement of research infrastructure by further development of shared resources * Completion of clinical and research facility remodeling and expansions

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014520-37S2
Application #
8144098
Study Section
Subcommittee G - Education (NCI)
Program Officer
Vanduyn, Maryann
Project Start
1976-01-01
Project End
2012-03-31
Budget Start
2010-04-29
Budget End
2011-03-31
Support Year
37
Fiscal Year
2010
Total Cost
$148,912
Indirect Cost
Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Liu, Bai; Jones, Monica; Kong, Lin et al. (2018) Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models. Cytokine 107:105-112
Yu, Deyang; Yang, Shany E; Miller, Blake R et al. (2018) Short-term methionine deprivation improves metabolic health via sexually dimorphic, mTORC1-independent mechanisms. FASEB J 32:3471-3482
Carroll, Molly J; Fogg, Kaitlin C; Patel, Harin A et al. (2018) Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells. Cancer Res 78:3560-3573
Ehlerding, Emily B; Grodzinski, Piotr; Cai, Weibo et al. (2018) Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics. ACS Nano 12:2106-2121
Park, Linda; Schwei, R J; Xiong, P et al. (2018) Addressing Cultural Determinants of Health for Latino and Hmong Patients with Limited English Proficiency: Practical Strategies to Reduce Health Disparities. J Racial Ethn Health Disparities 5:536-544
Ehlerding, Emily B; Lan, Xiaoli; Cai, Weibo (2018) ""Albumin Hitchhiking"" with an Evans Blue Analog for Cancer Theranostics. Theranostics 8:812-814
Morris, Zachary S; Guy, Emily I; Werner, Lauryn R et al. (2018) Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites. Cancer Immunol Res 6:825-834
Yu, Bo; Goel, Shreya; Ni, Dalong et al. (2018) Reassembly of 89 Zr-Labeled Cancer Cell Membranes into Multicompartment Membrane-Derived Liposomes for PET-Trackable Tumor-Targeted Theranostics. Adv Mater 30:e1704934
England, Christopher G; Jiang, Dawei; Ehlerding, Emily B et al. (2018) 89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging 45:110-120
Rutter, Carolyn M; Kim, Jane J; Meester, Reinier G S et al. (2018) Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev 27:158-164

Showing the most recent 10 out of 1528 publications